Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonilla-Abadía, Fabio, Coronel Restrepo, Nicolás, Tobón, Gabriel J., Echeverri, Andrés F., Muñoz-Buitrón, Evelyn, Castro, Andres Mauricio, Bejarano, Mercedes Andrade, Cañas, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914290/
https://www.ncbi.nlm.nih.gov/pubmed/24527208
http://dx.doi.org/10.1155/2014/731806
_version_ 1782302379456069632
author Bonilla-Abadía, Fabio
Coronel Restrepo, Nicolás
Tobón, Gabriel J.
Echeverri, Andrés F.
Muñoz-Buitrón, Evelyn
Castro, Andres Mauricio
Bejarano, Mercedes Andrade
Cañas, Carlos A.
author_facet Bonilla-Abadía, Fabio
Coronel Restrepo, Nicolás
Tobón, Gabriel J.
Echeverri, Andrés F.
Muñoz-Buitrón, Evelyn
Castro, Andres Mauricio
Bejarano, Mercedes Andrade
Cañas, Carlos A.
author_sort Bonilla-Abadía, Fabio
collection PubMed
description Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
format Online
Article
Text
id pubmed-3914290
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39142902014-02-13 Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus Bonilla-Abadía, Fabio Coronel Restrepo, Nicolás Tobón, Gabriel J. Echeverri, Andrés F. Muñoz-Buitrón, Evelyn Castro, Andres Mauricio Bejarano, Mercedes Andrade Cañas, Carlos A. Autoimmune Dis Research Article Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment. Hindawi Publishing Corporation 2014 2014-01-16 /pmc/articles/PMC3914290/ /pubmed/24527208 http://dx.doi.org/10.1155/2014/731806 Text en Copyright © 2014 Fabio Bonilla-Abadía et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bonilla-Abadía, Fabio
Coronel Restrepo, Nicolás
Tobón, Gabriel J.
Echeverri, Andrés F.
Muñoz-Buitrón, Evelyn
Castro, Andres Mauricio
Bejarano, Mercedes Andrade
Cañas, Carlos A.
Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title_full Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title_fullStr Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title_full_unstemmed Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title_short Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
title_sort rituximab for remission induction and maintenance in refractory systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914290/
https://www.ncbi.nlm.nih.gov/pubmed/24527208
http://dx.doi.org/10.1155/2014/731806
work_keys_str_mv AT bonillaabadiafabio rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT coronelrestreponicolas rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT tobongabrielj rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT echeverriandresf rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT munozbuitronevelyn rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT castroandresmauricio rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT bejaranomercedesandrade rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus
AT canascarlosa rituximabforremissioninductionandmaintenanceinrefractorysystemiclupuserythematosus

Ejemplares similares